摘要
目的探讨利培酮与奥氮平治疗难治性精神分裂症的临床价值,以期提高临床疗效,保障用药的安全性。方法随机将我院2016年6月—2017年6月收治的60例难治性精神分裂症患者分为两组,每组30例。观察组给予奥氮平,对照组给予利培酮,比较两组临床疗效。结果治疗后,观察组PANSS评分、总有效率以及不良反应发生率等明显优于对照组,差异有统计学意义(P <0.05)。结论与利培酮相比,奥氮平治疗难治性精神分裂症具有良好的效果,它不仅提高了临床疗效,同时用药安全性较高,有利于改善患者的治疗依从性,从而保障了患者的身体健康和生活质量。
Objective To investigate the clinical value of risperidone and olanzapine in the treatment of refractory schizophrenia,in order to improve clinical efficacy and ensure the safety of medication.Methods 60 patients with refractory schizophrenia admitted to our hospital from June 2016 to June 2017 were randomly divided into two groups,30 in each group.The observation group was given olanzapine,and the control group was given risperidone.The clinical efficacy of the two groups was compared.Results After treatment,the PANSS score,total effective rate,and incidence of adverse reactions in the observation group were significantly better than those in the control group,and the difference was significant (P < 0.05).Conclusion Compared with risperidone,olanzapine has a good effect in the treatment of refractory schizophrenia.It not only improves the clinical efficacy,but also has a high safety of medication,which is beneficial to improve the patient's treatment compliance,and the health and quality of life of patients are guaranteed.
作者
孙莹莹
SUN Yingying(Psychiatry Department,Mudanjiang Nanshan Hospital,Mudanjiang Heilongjiang 157000,China)
出处
《中国卫生标准管理》
2019年第7期62-64,共3页
China Health Standard Management
